New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
06:41 EDTIPXLImpax price target raised to $35 from $27 at Piper Jaffray
Piper Jaffray raised its price target for Impax shares to $35 saying it sees more upside potential than downside risk even with the absence of a resolution of the FDA warning letter related to the Hayward manufacturing facility. Piper reiterates an Overweight rating on the stock.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:18 EDTIPXLAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
10:00 EDTIPXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:58 EDTIPXLImpax downgraded to Sell from Neutral at UBS
UBS downgraded Impax Laboratories to Sell saying the risk/reward is biased to the downside following the recent rally in shares. UBS attributes the recent run-up in shares to expectations the company will do more deals or get acquired. The firm does not see either scenario driving the stock much above current levels "any time soon." It keeps a $36 price target for Impax shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use